Physician profile
Alyssa M Hackett
NPI 1063677482
$1,146.82
in general payments reported to CMS, 2019-2025
13 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Pediatric Otolaryngology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $190 · 2023: $421 · 2024: $384 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $443.61 | 2022-2025 | |
| Glaxosmithkline, LLC. | $165.31 | 2022-2023 | Nucala |
| Acclarent, INC | $84.97 | 2022 | |
| Inspire Medical Systems, INC. | $77.34 | 2023-2024 | Inspire |
| Integra Lifesciences Corporation | $73.58 | 2024-2025 | Acclarent Aera, Inspira Air, Trudi Probe |
| Hikma Pharmaceuticals USA | $62.44 | 2022-2024 | Ryaltris |
| Regeneron Healthcare Solutions, INC. | $59.23 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $58.28 | 2025 | |
| Kaleo, INC. | $42.52 | 2023-2024 | Auvi-Q |
| Abbvie INC. | $28.20 | 2022 | |
| Neurent Medical Limited | $23.43 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Smith+Nephew, INC. | $15.06 | 2024 | Halo, Tula, Rapid Rhino |
| Astrazeneca Pharmaceuticals LP | $12.85 | 2023 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Hackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.